Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2025-06-24
DOI
https://doi.org/10.1093/oncolo/oyaf189
Citations
1
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer

Qiao Huang, Bo Pei, Zhimin Gong, Lei Wang et al.
1 citations
The Oncologist
Gastric Cancer Management and Outcomes
1.52
article

Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer

Qiao Huang, Bo Pei, Zhimin Gong, Lei Wang, Li Kuang, Xianglin Yuan, Li Sun, Hong Qiu
article en
1 citations

Abstract

No abstract available for this paper.
The OncologistVol. 30(7)
China Three Gorges University (CN), Hubei University of Arts and Science (CN), The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (CN), Xiangyang Central Hospital (CN), Dongfeng General Hospital (CN), Tongji Hospital (CN), Huazhong University of Science and Technology (CN)
Huazhong University of Science and Technology, National Key Research and Development Program of China
Good health and well-being
Openalex Percentile: Top 17%
Gastric Cancer Management and Outcomes
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer — Qiao Huang, Bo Pei, et al. · The Oncologist (2025) | TGRS Research Map | TGRS